Wednesday, December 13, 2006 7:30:00 AM PDT | VentureDeal Staff
CHAPEL HILL, NC -- Asklepios BioPharmaceuticals has landed a $2.5 million grant from the Muscular Dystrophy Association to continue clinical human trials of its gene therapy for Duchenne muscular dystrophy. The grant is the largest ever by the Muscular Dystrophy Association and will be matched by the company. The purpose of the trials is to deliver the therapy into multiple muscles in animals, since it has proven to be safe in single muscle human trials. The privately-held company was originally spun out of the University of North Carolina at Chapel Hill.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
